

LION BIOSCIENCE AG
Form 6-K
November 13, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

**Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

LION BIOSCIENCE AKTIENGESELLSCHAFT

(Exact Name of Registrant as Specified in its Charter)

FEDERAL REPUBLIC OF GERMANY

(Jurisdiction of Incorporation or Organization)

Im Neuenheimer Feld 515-517

D-69120 Heidelberg

Germany

(Address of Principal Executive Offices)

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐

No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not Applicable

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

LION bioscience Aktiengesellschaft's Report for the six month period ended September 30, 2003 is attached as Exhibit 99.1 and incorporated by reference in this Form 6-K.

This Report of Foreign Private Issuer on Form 6-K is specifically incorporated by reference in the Company's Registration Statement of Form F-3 (Reg. No. 333-90730) filed on June 18, 2002, as amended on July 16, 2002.

This report is identical to the Report filed with the U.S. Securities and Exchange Commission (SEC) on November 10, 2003 except for certain formatting changes to correct the number formatting of the Report as filed on November 10, 2003. The Report filed on November 10, 2003 contained certain inadvertent number formatting errors that resulted from the conversion of the document into the U.S. English format for filing with the SEC.

Any statements contained in this documents that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as anticipate, believe, estimate, expect, forecast, intend, may, plan, project, predict and similar expressions as they related to the Company are intended to identify such forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect the Company's future financial results are discussed more fully in the Company's filings with the SEC, including the Company's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

<u>Exhibit No.</u>	<u>Exhibit</u>
99.1	Report for the six month period ended September 30, 2003

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LION bioscience Aktiengesellschaft

By: /s/ Dr. Friedrich von Bohlen und Halbach

Dr. Friedrich von Bohlen und
Halbach
Chief Executive Officer

Dated: November 13, 2003